These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 33308179)

  • 1. Network meta-analysis of targeted therapies for diffuse large B cell lymphoma.
    Wang J; Huang J; Zeng Q
    BMC Cancer; 2020 Dec; 20(1):1218. PubMed ID: 33308179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab treatment strategy for patients with diffuse large B-cell lymphoma after first-line therapy: a systematic review and meta-analysis.
    Ren YR; Jin YD; Zhang ZH; Li L; Wu P
    Chin Med J (Engl); 2015 Feb; 128(3):378-83. PubMed ID: 25635435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of lenalidomide in diffuse large B-cell lymphoma: a meta-analysis of randomized controlled trials.
    Liu J; Mi R; Chen L; Guo X; Liang T; Yin Q
    Clin Exp Med; 2023 Aug; 23(4):1161-1169. PubMed ID: 36315313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of maintenance therapy in patients with diffuse large B cell lymphoma: A systematic review and meta-analysis.
    Rozental A; Gafter-Gvili A; Vidal L; Raanani P; Gurion R
    Hematol Oncol; 2019 Feb; 37(1):27-34. PubMed ID: 30216478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis.
    Zhou X; Ma T; Zhang Y; Zhou N; Li J
    PLoS One; 2017; 12(3):e0174648. PubMed ID: 28355276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review.
    Colosia A; Njue A; Trask PC; Olivares R; Khan S; Abbe A; Police R; Wang J; Ruiz-Soto R; Kaye JA; Awan F
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):343-355.e6. PubMed ID: 24768510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial.
    Fayad L; Ansell SM; Advani R; Coiffier B; Stuart R; Bartlett NL; Forero-Torres A; Kuliczkowski K; Belada D; Ng E; Drachman JG
    Leuk Lymphoma; 2015; 56(9):2569-78. PubMed ID: 25651427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
    Thieblemont C; Tilly H; Gomes da Silva M; Casasnovas RO; Fruchart C; Morschhauser F; Haioun C; Lazarovici J; Grosicka A; Perrot A; Trotman J; Sebban C; Caballero D; Greil R; van Eygen K; Cohen AM; Gonzalez H; Bouabdallah R; Oberic L; Corront B; Choufi B; Lopez-Guillermo A; Catalano J; Van Hoof A; Briere J; Cabeçadas J; Salles G; Gaulard P; Bosly A; Coiffier B
    J Clin Oncol; 2017 Aug; 35(22):2473-2481. PubMed ID: 28426350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
    Camicia R; Winkler HC; Hassa PO
    Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line targ veted therapies of advanced hepatocellular carcinoma: A Bayesian network analysis of randomized controlled trials.
    Ding W; Tan Y; Qian Y; Xue W; Wang Y; Jiang P; Xu X
    PLoS One; 2020; 15(3):e0229492. PubMed ID: 32134981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
    Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
    J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Ivanov V; Coso D; Chetaille B; Esterni B; Olive D; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Broussais-Guillaumot F; Blaise D; Bouabdallah R
    Leuk Lymphoma; 2014 Nov; 55(11):2508-13. PubMed ID: 24506467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era.
    Sun F; Zhu J; Lu S; Zhen Z; Wang J; Huang J; Ding Z; Zeng M; Sun X
    BMC Cancer; 2018 Jan; 18(1):5. PubMed ID: 29291712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis.
    Lin Z; Chen X; Li Z; Zhou Y; Fang Z; Luo Y; Zhao J; Xu B
    Ann Hematol; 2018 Nov; 97(11):2137-2144. PubMed ID: 30027435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis.
    Hou K; Yu Z; Jia Y; Fang H; Shao S; Huang L; Feng Y
    Crit Rev Oncol Hematol; 2020 Aug; 152():103010. PubMed ID: 32540781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?
    Di Rocco A; De Angelis F; Ansuinelli M; Foà R; Martelli M
    Expert Rev Hematol; 2017 Sep; 10(9):761-774. PubMed ID: 28712322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
    Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
    Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma.
    Chiappella A; Santambrogio E; Castellino A; Nicolosi M; Vitolo U
    Expert Rev Hematol; 2017 Aug; 10(8):697-705. PubMed ID: 28665232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL.
    Li L; Zhang X; Zhang T; Song Z; Hu G; Li W; Li L; Qiu L; Qian Z; Zhou S; Liu X; Feng L; Pan Y; Zhai Q; Meng B; Ren X; Fu K; Wang P; Wang X; Zhang H
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):e381-e389. PubMed ID: 29983382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.